X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Expected to Rise, HC Wainwright Analyst Says

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) had its target price increased by equities researchers at HC Wainwright from $1.50 to $7.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 86.67% from the company's current price.

Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $90.00 price objective on shares of X4 Pharmaceuticals in a research report on Wednesday, March 26th.

X4 Pharmaceuticals Stock Performance

NASDAQ:XFOR opened at $3.75 on Friday. The business's fifty day moving average is $7.86 and its 200 day moving average is $13.28. X4 Pharmaceuticals has a 52-week low of $3.70 and a 52-week high of $36.00. The firm has a market cap of $651.23 million, a price-to-earnings ratio of -41.66 and a beta of 0.58. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($6.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.10) by ($0.90). The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.07 million. Research analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current year.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of XFOR. Acorn Capital Advisors LLC purchased a new position in shares of X4 Pharmaceuticals in the fourth quarter valued at about $5,363,000. JPMorgan Chase & Co. raised its stake in X4 Pharmaceuticals by 501.0% during the fourth quarter. JPMorgan Chase & Co. now owns 459,653 shares of the company's stock valued at $337,000 after purchasing an additional 383,177 shares in the last quarter. Jane Street Group LLC raised its position in shares of X4 Pharmaceuticals by 134.9% during the 4th quarter. Jane Street Group LLC now owns 583,483 shares of the company's stock valued at $428,000 after buying an additional 335,036 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of X4 Pharmaceuticals by 559.6% in the 4th quarter. Deutsche Bank AG now owns 267,628 shares of the company's stock valued at $195,000 after purchasing an additional 227,051 shares during the last quarter. Finally, Barclays PLC lifted its position in X4 Pharmaceuticals by 196.0% in the third quarter. Barclays PLC now owns 277,682 shares of the company's stock worth $185,000 after buying an additional 183,861 shares during the last quarter. Institutional investors own 72.03% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.